Contents
- Coronavirus. The antibodies kasirivimab and imdevimab reduce the risk of hospitalization
- Coronavirus. An antibody cocktail reduced the risk of hospitalization and death by 87 percent
- COVID-19 monoclonal antibodies – how they work
- The FDA approves the COVID-19 antibody cocktail
- Coronavirus. Kasirivimab and imdewimab – first studies
Swiss pharmaceutical company Roche announced that administration of the cocktail of antibodies kasirivimab and imdewimab reduces the need for hospitalization in people with mild symptoms of COVID-19. This is another research showing the effectiveness of monoclonal antibody therapy. Earlier reports on the effects of these antibodies were assessed by Bartosz Fiałek as phenomenal.
- Third wave of COVID-19 on the attack. According to doctors and scientists, mass vaccination may prevent us from becoming infected again
- At the same time, research on effective therapies for people already infected with the coronavirus is ongoing. One way may be by administering a monoclonal antibody cocktail
- More promising research results have just emerged in people given the antibodies kasirivimab and imdevimab
- Do you want to live longer? Make a simple test and find out how!
- You can find more such stories on the TvoiLokony home page
The Swiss company Roche announced on Tuesday the promising results of clinical trials of an experimental antibody cocktail therapy conducted in cooperation with the US drug manufacturer Regeneron. The therapy is intended for patients with mild to moderate COVID-19 symptoms.
The antibody cocktail tested combines the antibodies kasirivimab and imdevimab. The data from the phase III study showed 70 percent. reducing hospitalizations or deaths in patients with COVID-19 who did not require hospitalization – stated in the message.
Studies have also shown that the duration of coronavirus symptoms has decreased from 14 days to 10 days.
In addition, parallel phase II tests showed that the therapy the antibodies of kasirivimab and imdevimab significantly reduced the amount of coronavirus in patients not requiring hospitalization with COVID-19, both symptomatic and asymptomatic.
A few days ago, Bartosz Fiałek, a specialist in the field of rheumatology and promoter of medical knowledge, wrote about similar studies on Facebook.
The study was conducted by scientists from the American pharmaceutical company Eli Lilly, and more than 750 patients at high risk of severe infection with SARS-CoV-2 participated in it. It found that the cocktail of monoclonal antibodies reduced the risk of hospitalization and death from COVID-19 by as much as 87 percent. Back then it was a mixture of bamlanivimab and etesewimab.
«The results are phenomenal» – assessed Fiałek.
- Read: The antibody cocktail protects against the severe course of COVID-19. «Phenomenal results»
COVID-19 monoclonal antibodies – how they work
Bartosz Fiałek previously wrote that “the medical world places the greatest hope in monoclonal antibodies”.
— In addition to the COVID-19 vaccines, treatment trials are underway. After all, until herd immunity is obtained, we must have drugs at our disposal in order to be able to help as many patients as possible – explained Fiałek.
- How to prepare for the COVID-19 vaccination? 12 expert advice
The task of the antibodies is to inactivate the pathogen. Monoclonal antibodies, unlike those produced by the immune system – do not arise naturally, they are produced in laboratories. They are modified proteins that mimic natural antibodies to fight viruses. They are supposed to help reduce the amount of the pathogen in the body and give our body time to produce its own antibodies.
Monolocal antibodies are proteins produced by one clone of B lymphocytes, so that each antibody is identical and acts on exactly the same antigen.
The FDA approves the COVID-19 antibody cocktail
In November, the US Food and Drug Administration (FDA) authorized Regeneron to use an emergency use authorization (EUA) antibody to kasirivimab and imdevimab to treat mild to moderate COVID-19 in people over 12 years of age. and weighing more than 40 kg, who are at risk of developing severe COVID-19.
High-risk factors defined by the FDA include diabetes, immunosuppressive therapy, chronic kidney disease, obesity, age over 65, as well as cardiovascular disease, hypertension, lung disease in patients over 55, and severe obesity, anemia, heart disease, asthma or other chronic diseases in many people 12 -17 years.
- Who is at risk of severe COVID-19? Scientists found several factors
“Authorizing these monoclonal antibody therapies could help outpatients avoid hospitalization and reduce the burden on the healthcare system,” said FDA commissioner MD. Med. Stephen M. Hahn.
However, it should be emphasized that REGEN-COV, a mixture of antibodies, has not been officially approved by the FDA, it has only been approved for emergency use.
The FDA approval studies were conducted in 799 non-hospitalized adults with mild to moderate symptoms of COVID-19. In this group – within three days of testing positive for coronavirus – 266 people received a dose of 1200 milligrams of kasirivimab and 1200 mg of imdevimab, 267 received 4000 mg of kasirivimab and oimdewimab, and 266 received a placebo.
- Prof. Marten: Lockdown is evil, it will shorten our lives and cause epidemics of other diseases
Relief of COVID-19 symptoms occurred more frequently in those who received the antibodies than in those given a placebo. In the case of patients at high risk of developing severe symptoms of coronavirus, the need for hospitalization occurred in 3% of patients. patients treated with kasirivimab and imdevimab, and in 9% placebo-treated patients.
The FDA also noted that kasirivimab and imdevimab are not approved for use in patients already hospitalized for COVID-19 or requiring oxygen therapy. Monoclonal antibodies administered to hospitalized patients requiring mechanical ventilation may be associated with worsening of clinical outcomes.
Read also:
- How many people in Poland died after the COVID-19 vaccine? Government data
- Doctors tell you how to know if COVID-19 has left traces in your body
- It even surprised scientists. The pandemic didn’t start in Wuhan?
- EMA: AstraZeneca vaccine is safe and effective
The content of the medTvoiLokony website is intended to improve, not replace, the contact between the Website User and their doctor. The website is intended for informational and educational purposes only. Before following the specialist knowledge, in particular medical advice, contained on our Website, you must consult a doctor. The Administrator does not bear any consequences resulting from the use of information contained on the Website. Do you need a medical consultation or an e-prescription? Go to halodoctor.pl, where you will get online help – quickly, safely and without leaving your home.Now you can use e-consultation also free of charge under the National Health Fund.